A Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions (IMISC)


About this study

The purpose of this study is to create a research registry of patients with Immune-Mediated Inflammatory Skin Conditions (IMISC) within academic and community, real-world practices in order to assess the safety and effectiveness of current and future therapies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Adults and children (all ages).
  • Have Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions and have been prescribed any dermatologic treatment.
  • Participant has plans for future visits at the site for continued management of IMISC.

Exclusion Criteria:

  • Inability to provide written informed consent/assent. 
  • Subjects participating in any interventional study or trial for Immune-Mediated Inflammatory Skin Conditions (IMISC)treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete.
    • Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Megha Tollefson, M.D.

Open for enrollment

Contact information:

Jessica Hafeman

(507) 422-6964


More information


Publications are currently not available

Mayo Clinic Footer